2023. december 6., szerda 16:00 |
LTS receives grant of $1.2 Million to support the development of thermostable mRNA formulations for Microneedle Array Patches |
|
Andernach, 6 December, 2023 (APA/OTS) - LTS, a leading pharmaceutical technology company, announced today that it has received a grant from the Bill & Melinda Gates Foundation. The grant will support new formulation methods for mRNA, such as dissolvable microneedle array patches (MAPs), to increase the thermostability of the overall product for its use in low- and middle-income countries (LMICs), especially in hard-to-reach conditions. This grant will fund $1.2 million over a duration of 15 months. |
mRNA technology is considered a potential game-changer for a range
of infectious diseases, including tuberculosis, malaria, and Lassa
fever, which disproportionately affect people in LMICs. One of the
major challenges the world faces in getting these life-saving
vaccines to vulnerable populations - particularly those in poorer
countries - is the need to store them at very low temperatures. The
need for frozen storage of the current generation of mRNA vaccines
is due to the fragility of mRNA molecules. The incorporation of mRNA
into a dissolvable MAP may overcome this challenge by protecting the
mRNA against degradation, removing the need for frozen storage, and
simplifying the access to people living in LMICs.
At the World Vaccine Congress in Barcelona, LTS recently presented
pre-clinical data from an mRNA/LNP MAP-based vaccination against
rabies, from a collaboration with a biopharmaceutical company. This
successful pre-clinical study with mRNA/LNP vaccine against rabies
demonstrated that the cold-chain requirements can be reduced from
-80?C to 2-8?C by using a MAP instead of an injectable formulation.
MAPs are an innovative drug delivery technology that offers
advantages in comparison to established drug delivery applications,
such as the opportunity for dose-sparing, lowering requirements for
cold-chain and the possibility for self-administration.
Bas van Buijtenen, CEO of LTS, commented: "At LTS, we care
passionately about bringing patient friendly drug delivery to people
worldwide. We are honoured to be receiving support from the Gates
Foundation in creating solutions for populations that would
otherwise be at risk of being left behind. With MAPs, we aim to
deliver improved access to essential vaccines to these groups,
potentially saving lives."
"The LTS MAP team is excited to have support from the Gates
Foundation for the development of a thermostable mRNA/LNP MAP", said
Dr. Frank Theobald, Head of MAP Program at LTS. "LTS has made great
progress recently with its MAP Program with respect to pre-clinical
and clinical data, taking steps towards the up-scaling and
commercialization of the MAP technology. LTS believes that MAPs will
be a breakthrough technology for improving vaccination coverage in
LMICs. Support from the foundation will help to develop the MAP
technology further and bring it to the next level of maturity and
make it accessible for patients in the foreseeable future."
Picture is available at AP -
https://apmultimedianewsroom.com/multimedia-newsroom/partners/news-aktuell
About LTS We CARE. We CREATE. We DELIVER. The driving philosophy behind LTS.
As a trusted technology partner for the pharmaceutical industry, we
develop and manufacture innovative drug delivery systems such as
Transdermal Patches ("TTS") and Oral Thin Films ("OTF") as well as
wearable drug delivery devices ("OBDS"). LTS´ commercial offering
encompasses more than 20 marketed products and a diverse pipeline of
more than 40 development projects targeting multiple disease
indications. LTS's innovation pipeline contains both partner-funded
as well as proprietary, LTS-funded projects. LTS maintains its
leading position through the continuous refinement of its core TTS
and OTF technologies and by advancing emerging drug delivery
technologies, including Microneedle Array Patches ("MAP") for the
transdermal delivery of small and large molecules, biological
actives and vaccines. With its SorrelTM wearable drug delivery
platform LTS offers patient friendly solutions for complex drugs
delivery at home. Founded in 1984, LTS operates today from four
sites: in Andernach, Germany, West Caldwell, NJ, USA, St. Paul, MN,
USA and Netanya, Israel. LTS has also a representative office in
Shanghai, China.
Contact Dr Iris Schnitzler iris.schnitzler@ltslohmann.com +49 2632 992589
LTS LOHMANN Therapy Systems AG Lohmannstrasse 2 56626 Andernach Germany Phone: +49 (0) 2632 99-0 Fax: +49 (0) 2632 99-22 00 info@ltslohmann.com www.ltslohmann.com
-------------------------------------------------------------------
Az OTS internetes oldalán található hírek, közlemények, fotók
a forrásmegjelöléssel (OTS) szabadon és korlátozás nélkül
felhasználhatók. Továbbközlés esetén a közzétevő köteles az átvett
anyagot tartalmának torzítása nélkül, félreérthetőséget,
rosszindulatú következtetéseket kizáró, az eredeti
szövegkörnyezetnek megfelelő módon feldolgozni és megjelentetni.
Az OTS hírek nem képezik az MTI hírkiadás részét, az MTI
által szó szerint továbbított tartalomért minden esetben a beadó a
felelős. © Copyright MTI nonprofit Zrt.
Az OTS szolgáltatással kapcsolatban további információt a
(06-1) 441-9050 telefonszámon vagy a ots@mti.hu elektronikus
levelező címen kaphat.
|
|
|
|
|
|
|
Forrás: OTS Üzleti Sajtószolgálat
MTI © Minden jog fenntartva.
|